.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AC21_Treprostinil.Treprostinil

Information

Treprostinil is a stable, synthetic analog of prostacyclin (PGI2) used primarily for the treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity. It acts as a vasodilator of pulmonary and systemic arterial vascular beds and inhibits platelet aggregation. It is approved for use in several countries and can be administered intravenously, subcutaneously, orally, or by inhalation.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers after intravenous administration.

References

1. Wu, X, et al., & Venkataramanan, R (2022). Physiologically based pharmacokinetic modelling of treprostinil after intravenous injection and extended-release oral tablet administration in healthy volunteers: An extrapolation to other patient populations including patients with hepatic impairment. British journal of clinical pharmacology 88(2) 587–599. DOI:10.1111/bcp.14966 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34190364

2. Galiè, N, et al., & Branzi, A (2003). Prostanoids for pulmonary arterial hypertension. American journal of respiratory medicine : drugs, devices, and other interventions 2(2) 123–137. DOI:10.1007/BF03256644 PUBMED:https://pubmed.ncbi.nlm.nih.gov/14720012

Revisions

• 06/2025 initial generated model